Oncolytics Biotech (TSE:ONC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Oncolytics Biotech Inc. is making significant strides in cancer treatment, with the FDA potentially accelerating approval of their breast cancer therapy, pelareorep. This development comes amid a global rise in cancer rates, with a 79% increase in new cases and a projected 77% increase by 2050. The company’s BRACELET-1 trial results are promising, setting the stage for a large study targeting HR+/HER2- metastatic breast cancer patients.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
